🎉 M&A multiples are live!
Check it out!

Cogent Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cogent Biosciences and other public comps.

See Cogent Biosciences Valuation Multiples

Cogent Biosciences Overview

About Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.


Founded

2014

HQ

United States of America
Employees

164

Website

cogentbio.com

Financials

LTM Revenue n/a

LTM EBITDA -$265M

EV

$680M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cogent Biosciences Financials

Cogent Biosciences has a last 12-month revenue of n/a and a last 12-month EBITDA of -$265M.

In the most recent fiscal year, Cogent Biosciences achieved revenue of n/a and an EBITDA of -$205M.

Cogent Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cogent Biosciences valuation multiples based on analyst estimates

Cogent Biosciences P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue n/a n/a n/a n/a XXX
Gross Profit n/a n/a n/a XXX XXX
Gross Margin NaN% NaN% NaN% XXX XXX
EBITDA -$142M -$205M -$264M -$265M XXX
EBITDA Margin -Infinity% -Infinity% -Infinity% -Infinity% XXX
Net Profit -$72.3M -$140M -$192M XXX XXX
Net Margin -Infinity% -Infinity% -Infinity% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Cogent Biosciences Stock Performance

As of February 14, 2025, Cogent Biosciences's stock price is $8.

Cogent Biosciences has current market cap of $887M, and EV of $680M.

See Cogent Biosciences trading valuation data

Cogent Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$680M $887M XXX XXX XXX XXX $-2.42

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cogent Biosciences Valuation Multiples

As of February 14, 2025, Cogent Biosciences has market cap of $887M and EV of $680M.

Cogent Biosciences's trades at n/a LTM EV/Revenue multiple, and -2.6x LTM EBITDA.

Analysts estimate Cogent Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cogent Biosciences and 10K+ public comps

Cogent Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $680M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -2.6x XXX XXX XXX
P/E -3.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cogent Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cogent Biosciences Valuation Multiples

Cogent Biosciences's NTM/LTM revenue growth is Infinity%

Cogent Biosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Cogent Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cogent Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cogent Biosciences and other 10K+ public comps

Cogent Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 29% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Cogent Biosciences Public Comps

See valuation multiples for Cogent Biosciences public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cogent Biosciences M&A and Investment Activity

Cogent Biosciences acquired  XXX companies to date.

Last acquisition by Cogent Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cogent Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cogent Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cogent Biosciences

When was Cogent Biosciences founded? Cogent Biosciences was founded in 2014.
Where is Cogent Biosciences headquartered? Cogent Biosciences is headquartered in United States of America.
How many employees does Cogent Biosciences have? As of today, Cogent Biosciences has 164 employees.
Who is the CEO of Cogent Biosciences? Cogent Biosciences's CEO is Mr. Andrews R. Robbins, M.B.A..
Is Cogent Biosciences publicy listed? Yes, Cogent Biosciences is a public company listed on NAS.
What is the stock symbol of Cogent Biosciences? Cogent Biosciences trades under COGT ticker.
When did Cogent Biosciences go public? Cogent Biosciences went public in 2018.
Who are competitors of Cogent Biosciences? Similar companies to Cogent Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cogent Biosciences? Cogent Biosciences's current market cap is $887M
What is the current EBITDA of Cogent Biosciences? Cogent Biosciences's last 12-month EBITDA is -$265M.
What is the current EV/EBITDA multiple of Cogent Biosciences? Current EBITDA multiple of Cogent Biosciences is -2.6x.
Is Cogent Biosciences profitable? Yes, Cogent Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.